EE9900278A - Angiotensiin II antagonistid kasutamiseks sümptomaatilise südamepuudulikkuse ravis - Google Patents

Angiotensiin II antagonistid kasutamiseks sümptomaatilise südamepuudulikkuse ravis

Info

Publication number
EE9900278A
EE9900278A EEP199900278A EEP9900278A EE9900278A EE 9900278 A EE9900278 A EE 9900278A EE P199900278 A EEP199900278 A EE P199900278A EE P9900278 A EEP9900278 A EE P9900278A EE 9900278 A EE9900278 A EE 9900278A
Authority
EE
Estonia
Prior art keywords
heart failure
angiotensin
symptomatic heart
antagonists
treatment
Prior art date
Application number
EEP199900278A
Other languages
English (en)
Inventor
A. Beere Polly
I. Chang Paul
Pitt Bertram
J. Rucinska Ewa
Segal Robert
Sharma Divakar
B. Snavely Duane
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704197.4A external-priority patent/GB9704197D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of EE9900278A publication Critical patent/EE9900278A/et

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
EEP199900278A 1997-01-10 1998-01-07 Angiotensiin II antagonistid kasutamiseks sümptomaatilise südamepuudulikkuse ravis EE9900278A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3492797P 1997-01-10 1997-01-10
GBGB9704197.4A GB9704197D0 (en) 1997-02-28 1997-02-28 Method for reducing mortality with an angiotensin 11 antagonist
PCT/US1998/000534 WO1998030216A1 (en) 1997-01-10 1998-01-07 Use of angiotensin ii antagonists to treat symptomatic heart failure

Publications (1)

Publication Number Publication Date
EE9900278A true EE9900278A (et) 2000-02-15

Family

ID=26311085

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900278A EE9900278A (et) 1997-01-10 1998-01-07 Angiotensiin II antagonistid kasutamiseks sümptomaatilise südamepuudulikkuse ravis

Country Status (18)

Country Link
EP (1) EP0966282B1 (et)
JP (1) JP2000508347A (et)
KR (1) KR20000070046A (et)
CN (1) CN1249682A (et)
AT (1) ATE243515T1 (et)
AU (1) AU729881B2 (et)
CA (1) CA2277018C (et)
DE (1) DE69815822T2 (et)
DK (1) DK0966282T3 (et)
EA (1) EA199900635A1 (et)
EE (1) EE9900278A (et)
ES (1) ES2200310T3 (et)
HU (1) HUP0000108A2 (et)
IL (1) IL130599A0 (et)
NO (1) NO993399L (et)
PT (1) PT966282E (et)
SK (1) SK92899A3 (et)
WO (1) WO1998030216A1 (et)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
SE9902597D0 (sv) * 1999-07-06 1999-07-06 Astra Ab New use
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
KR20030016229A (ko) * 2000-02-18 2003-02-26 다케다 야쿠힌 고교 가부시키가이샤 TNF-α 억제제
JP2005126338A (ja) * 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg 心不全治療剤
AR078107A1 (es) * 2009-08-31 2011-10-12 Sanofi Aventis Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca
PL3626270T3 (pl) * 2013-08-26 2024-04-08 Novartis Ag Leczenie chorób sercowo-naczyniowych
CA3029630A1 (en) 2016-06-29 2018-01-04 Universite De Montreal Biarylmethyl heterocycles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040257A1 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and angiotensin ii antagonist combination therapy for treatment of congestive heart failure

Also Published As

Publication number Publication date
DE69815822D1 (de) 2003-07-31
WO1998030216A1 (en) 1998-07-16
CA2277018A1 (en) 1998-07-16
NO993399D0 (no) 1999-07-09
DK0966282T3 (da) 2003-09-29
NO993399L (no) 1999-09-09
HUP0000108A2 (hu) 2001-04-28
AU729881B2 (en) 2001-02-15
EP0966282A1 (en) 1999-12-29
ES2200310T3 (es) 2004-03-01
EA199900635A1 (ru) 2000-02-28
CA2277018C (en) 2006-10-03
SK92899A3 (en) 2000-08-14
KR20000070046A (ko) 2000-11-25
IL130599A0 (en) 2000-06-01
DE69815822T2 (de) 2004-05-06
AU6021898A (en) 1998-08-03
ATE243515T1 (de) 2003-07-15
EP0966282B1 (en) 2003-06-25
PT966282E (pt) 2003-10-31
CN1249682A (zh) 2000-04-05
JP2000508347A (ja) 2000-07-04

Similar Documents

Publication Publication Date Title
EA200100418A1 (ru) Комбинированная терапия с применением ингибитора фермента конверсии ангиотензина и антагониста альдостерона для снижения заболеваемости и смертности при сердечно-сосудистых заболеваниях
BR9714363A (pt) Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas
TR200002860T2 (tr) Bir antiviral benzimidazol terkibin yeni kristal formları.
BR9711447A (pt) Uso de glp-1 an logos no tratamento de enfarte de mioc rdio
ES2167571T3 (es) Terapia de combinacion de antagonista de aldosterona epoxi-esteroideo y antagonista de angiotensina ii para el tratamiento del fallo cardiaco congestivo.
ES2084702T3 (es) Imidazoles sustituidos utiles como inhibidores de la angiotensina ii.
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
TR199500832A2 (tr) Benzimidazol türevleri ve bunlarin medikal terapide kullanimi ve bunlari iceren farmasötik formülasyonlar.
ATE232865T1 (de) 1,4-diazabicyclo(3.2.2)nonan-4-carboxylat und carboxamidderivate, ihre herstellung und therapeutische verwendung
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
TR200101470T2 (tr) Farmasötik bileşim terkipleri.
DK1572230T3 (da) Placenta alkalisk phosphatase til at kontrollere diabetes
ATE227717T1 (de) 3-pyridylenantiomere und ihre verwendung als analgetika
TR200102977T2 (tr) Yeni tedavi yöntemi.
DE69826684D1 (de) Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendungen
DE69814394D1 (de) Verwendung von levobupivacain
NO870772L (no) Vevplasminogenaktivator for normale humane tykktarmceller.
EE9900278A (et) Angiotensiin II antagonistid kasutamiseks sümptomaatilise südamepuudulikkuse ravis
FI20011464A0 (fi) Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
ES2166816T3 (es) Derivados piridil-imidazolicos y procedimientos para su preparacion.
CA2091134A1 (en) Therapeutic agent for threatened abortion
DK1478362T3 (da) Kombinationsbehandling til akut myokardisk infarkt
SE8902458L (sv) Laekemedelskomposition
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
TR199701617T1 (xx) �iftliklerde �retilen bal�klarda g�r�len parazitlerle m�cadelede kullan�lacak bir ajan.